Developer docs
API playgroundTry for free, no card

Search company profiles

CoreMedic GmbH

Full company profile

uuid00083sj

Namestring
CoreMedic GmbH
Legal namestring
CoreMedic GmbH
Websiteurl
coremedic.de
Company typeenum
Private
Founded yearint
2012
Descriptiontext

CoreMedic GmbH is a private medical technology company developing transcatheter devices for the treatment of heart valve diseases, with a primary focus on mitral valve regurgitation (MR). The company originated as a 2012 spin-out from the Heart Center of the University of Bern, Switzerland, became operationally independent in 2014, and relocated to Radolfzell am Bodensee, Germany in 2017 to anchor itself in the Tuttlingen medical technology cluster. Its lead product, the ChordArt Transcatheter Mitral Valve Repair (TMVr) System, is a catheter-based device that replaces damaged or elongated mitral valve chords through a minimally invasive transfemoral, transseptal route, eliminating the need for open-heart surgery. The system is positioned as a first-line treatment for Primary Mitral Regurgitation and is described as the world's first transcatheter chordal replacement technology, supported by five-year clinical follow-up data demonstrating sustained safety, effectiveness, and structural durability of the implant.

The company operates a B2B go-to-market model targeting leading cardiac surgery centers and heart valve centers of excellence, primarily in Europe. Revenue is generated through hardware sales of the ChordArt system and adjacent professional services including physician training and proctoring. CoreMedic is currently in clinical development: the CHAGALL first-in-man trial is enrolling up to 40 patients across six European centers, and the company is pursuing CE marking for European market entry. The firm holds EN ISO 13485:2016 certification and is backed by institutional healthcare investors SHS Capital (since 2017) and MIG Capital (Series B extension in February 2025). Management and supervisory teams include veterans of Medtronic, Edwards Lifesciences, INVATEC, Abbott, and Jomed, with established KOL relationships across interventional cardiology and cardiac surgery in Europe.

Short descriptiontext

CoreMedic GmbH is a German clinical-stage medical technology company developing the ChordArt transcatheter mitral valve repair system for patients with mitral valve regurgitation ineligible for open-heart surgery. The pre-revenue firm targets leading European cardiac surgery centers and is pursuing CE marking.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRadolfzell, Germany
HQ citystring
Radolfzell
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transcatheter mitral valve repair, structural heart devices, cardiac surgery devices, chordal replacement implants, percutaneous valve repair
Industry1 code
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Transcatheter Mitral Valve Repair Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1ChordArt TMVr System Sales
TypeHardware Sales
Description

CoreMedic generates revenue through the sale of its ChordArt transcatheter mitral valve repair system, including the implant and catheter delivery components. The system is sold to cardiac surgery centers and hospitals for use in treating mitral valve regurgitation patients.

coremedic.de
2Professional Services and Training
TypeProfessional Services
Description

The company provides physician training, proctoring services, and clinical support as part of its commercial roll-out, helping cardiologists and cardiac surgeons adopt the technology.

coremedic.de
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CoreMedic develops and manufactures the ChordArt Transcatheter Mitral Valve Repair (TMVr) System, a catheter-based medical device designed to replace damaged or ruptured mitral valve chords through a minimally invasive transfemoral, transseptal percutaneous procedure. The system is sold to cardiac surgery centers and heart valve centers of excellence as a first-line treatment alternative to open-heart surgery for patients with primary mitral regurgitation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Technical success achieved in 100% of first 5 patients with MR reduction to no or trace residual MR (<1+/4+)
+5 more records
Product overview1 text field

CoreMedic GmbH offers a single unified product — the ChordArt Transcatheter Mitral Valve Repair (TMVr) System. This catheter-based device is designed to replace ruptured or elongated mitral valve chords through a minimally invasive percutaneous approach, providing an alternative to traditional open-heart surgery for patients with mitral valve regurgitation. The system enables chordal replacement via transfemoral, transseptal delivery, reducing patient trauma, procedure complexity, and recovery time compared to surgical gold standard.

Product and service1 record
1ChordArt TMVr-System
CategoryStructural Heart / Transcatheter Mitral Valve Repair
Description

A transcatheter mitral valve repair (TMVr) system designed to replace damaged mitral valve chords through a minimally invasive percutaneous procedure via transfemoral, transseptal route, enabling treatment of patients with mitral valve regurgitation who are not eligible for conventional open-heart surgery.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-10
Description

CoreMedic entered a strategic partnership with InnoRa GmbH, a German medical device company headquartered in Berlin specializing in cardiovascular devices since 2001. InnoRa contributes over 20 years of experience in cardiovascular device development and clinical trial translation. The partnership includes an undisclosed investment by InnoRa, with Professor Bruno Scheller (co-founder of InnoRa and renowned expert in interventional cardiology) joining CoreMedic's Supervisory Board.

2Clinical Advisors and KOL Network
Strategic tierCoreTypeOthers
Description

CoreMedic has assembled a network of internationally renowned clinical advisors including Prof. Thierry Carrel (cardiac surgeon with 700+ publications), Prof. Bruno Scheller (interventional cardiology expert), Prof. Maurizio Taramasso, Prof. Alberto Weber (Founder and CMO), and Prof. Rolf Vogel. These key opinion leaders provide scientific and clinical expertise and support the development and adoption of the ChordArt technology.

coremedic.de
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Abbott
TypeDirect peer
Description

Abbott's MitraClip is the established market leader in transcatheter mitral repair, and the Tendyne system targets transcatheter mitral replacement — directly competing with CoreMedic's ChordArt for the same patient population and cardiology customer base. Abbott's installed-base advantage in catheter-based structural heart interventions makes it the most consequential incumbent.

TypeEmerging player
Description

InnovHeart is developing the saturn TMVR system for transcatheter mitral valve replacement. It targets the same structural-heart customer base and MR patient population as CoreMedic with a replacement-focused approach.

TypeDirect peer
Description

NeoChord develops the NeoChord DS1000 system for beating-heart mitral chordal replacement, the closest technology analog to ChordArt's artificial chord replacement approach. While NeoChord is delivered surgically (transapical) rather than percutaneously, both companies pursue chordal replacement for degenerative MR and target cardiac surgery centers.

TypeBroad incumbent
Description

Medtronic is a broad cardiovascular incumbent with a structural heart portfolio (including Intrepid TMVR) and deep relationships with cardiac surgery centers. Multiple CoreMedic founders held leadership roles at Medtronic and Invatec (acquired by Medtronic), positioning Medtronic as both a talent feeder and potential strategic acquirer.

TypeEmerging player
Description

Cardiac Dimensions develops the Carillon Mitral Contour System, a transcatheter annuloplasty device for functional mitral regurgitation. It targets an overlapping patient population and customer base (interventional cardiologists and heart teams) with a different but adjacent transcatheter mitral repair mechanism.

TypeEmerging player
Description

HighLife Medical is developing a transcatheter mitral valve replacement system using a transseptal, transapical valve placement approach. Comparable European medtech with parallel TMVR development and similar regulatory pathway dynamics.

7Mitralign
TypeEmerging player
Description

Mitralign developed transcatheter annuloplasty systems for functional MR, directly competing for the same heart-failure MR patient segment with a percutaneous approach. Comparable mid-stage transcatheter mitral repair player with similar clinical-trial-stage commercialization pathway.

TypeDirect peer
Description

Edwards Lifesciences markets the PASCAL and PASCAL Ace transcatheter mitral valve repair systems, the most direct competitor to CoreMedic's ChordArt in the transcatheter chordal/leaflet repair space. Edwards also sets the bar for transcatheter heart valve trial design and commercialization, and Jodi Akin (CoreMedic's Chair) led seminal global trials and approvals of transcatheter heart valve therapy at Edwards.

TypeBroad incumbent
Description

Boston Scientific acquired Acotec (co-founded by CoreMedic co-founder Silvio Schaffner) in 2022 for its drug-coated balloon portfolio and is active in structural heart via its Watchman franchise. As a broad incumbent in interventional cardiology, Boston Scientific is both a potential strategic acquirer of CoreMedic and an indirect competitor in structural heart catheter-based therapies.

TypeEmerging player
Description

4C Medical is developing the AltaValve system for transcatheter mitral valve replacement (TMVR), addressing mitral regurgitation with a supra-annular implant design. Competitor for the same MR patient population served by CoreMedic, though with a replacement rather than repair approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CoreMedic GmbH

Transcatheter Mitral Valve Repair Devicescoremedic.de

CoreMedic GmbH is a German clinical-stage medical technology company developing the ChordArt transcatheter mitral valve repair system for patients with mitral valve regurgitation ineligible for open-heart surgery. The pre-revenue firm targets leading European cardiac surgery centers and is pursuing CE marking.

What CoreMedic GmbH does

CoreMedic GmbH is a private medical technology company developing transcatheter devices for the treatment of heart valve diseases, with a primary focus on mitral valve regurgitation (MR). The company originated as a 2012 spin-out from the Heart Center of the University of Bern, Switzerland, became operationally independent in 2014, and relocated to Radolfzell am Bodensee, Germany in 2017 to anchor itself in the Tuttlingen medical technology cluster. Its lead product, the ChordArt Transcatheter Mitral Valve Repair (TMVr) System, is a catheter-based device that replaces damaged or elongated mitral valve chords through a minimally invasive transfemoral, transseptal route, eliminating the need for open-heart surgery. The system is positioned as a first-line treatment for Primary Mitral Regurgitation and is described as the world's first transcatheter chordal replacement technology, supported by five-year clinical follow-up data demonstrating sustained safety, effectiveness, and structural durability of the implant.

The company operates a B2B go-to-market model targeting leading cardiac surgery centers and heart valve centers of excellence, primarily in Europe. Revenue is generated through hardware sales of the ChordArt system and adjacent professional services including physician training and proctoring. CoreMedic is currently in clinical development: the CHAGALL first-in-man trial is enrolling up to 40 patients across six European centers, and the company is pursuing CE marking for European market entry. The firm holds EN ISO 13485:2016 certification and is backed by institutional healthcare investors SHS Capital (since 2017) and MIG Capital (Series B extension in February 2025). Management and supervisory teams include veterans of Medtronic, Edwards Lifesciences, INVATEC, Abbott, and Jomed, with established KOL relationships across interventional cardiology and cardiac surgery in Europe.

CoreMedic GmbH firmographics

Firmographics
Name
CoreMedic GmbH
Legal name
CoreMedic GmbH
Website
https://coremedic.de
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
CoreMedic GmbH is a German clinical-stage medical technology company developing the ChordArt transcatheter mitral valve repair system for patients with mitral valve regurgitation ineligible for open-heart surgery. The pre-revenue firm targets leading European cardiac surgery centers and is pursuing CE marking.
Ownership category
akta.pro rank

CoreMedic GmbH industry classification

Industry
Product category
Transcatheter Mitral Valve Repair Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Transcatheter mitral valve repair
  • Structural heart devices
  • Cardiac surgery devices
  • Chordal replacement implants
  • Percutaneous valve repair

Where CoreMedic GmbH is headquartered

Location

Headquarters

HQ city
Radolfzell
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

CoreMedic GmbH business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. ChordArt TMVr System Sales: CoreMedic generates revenue through the sale of its ChordArt transcatheter mitral valve repair system, including the implant and catheter delivery components. The system is sold to cardiac surgery centers and hospitals for use in treating mitral valve regurgitation patients.
  2. Professional Services and Training: The company provides physician training, proctoring services, and clinical support as part of its commercial roll-out, helping cardiologists and cardiac surgeons adopt the technology.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

CoreMedic GmbH product offering

Product offering

Core offering

CoreMedic develops and manufactures the ChordArt Transcatheter Mitral Valve Repair (TMVr) System, a catheter-based medical device designed to replace damaged or ruptured mitral valve chords through a minimally invasive transfemoral, transseptal percutaneous procedure. The system is sold to cardiac surgery centers and heart valve centers of excellence as a first-line treatment alternative to open-heart surgery for patients with primary mitral regurgitation.

Product overview

CoreMedic GmbH offers a single unified product — the ChordArt Transcatheter Mitral Valve Repair (TMVr) System. This catheter-based device is designed to replace ruptured or elongated mitral valve chords through a minimally invasive percutaneous approach, providing an alternative to traditional open-heart surgery for patients with mitral valve regurgitation. The system enables chordal replacement via transfemoral, transseptal delivery, reducing patient trauma, procedure complexity, and recovery time compared to surgical gold standard.

Differentiator

Problem solved

Functional benefit

Products and services

  • ChordArt TMVr-System A transcatheter mitral valve repair (TMVr) system designed to replace damaged mitral valve chords through a minimally invasive percutaneous procedure via transfemoral, transseptal route, enabling treatment of patients with mitral valve regurgitation who are not eligible for conventional open-heart surgery.

Quantifiable outcome

  • Technical success achieved in 100% of first 5 patients with MR reduction to no or trace residual MR (<1+/4+)
  • +5 more outcomes

Companies that use CoreMedic GmbH

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles1 record

CoreMedic GmbH technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CoreMedic GmbH partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • InnoRa GmbHcoreStrategic or Co-development Partner · 10 January 2025CoreMedic entered a strategic partnership with InnoRa GmbH, a German medical device company headquartered in Berlin specializing in cardiovascular devices since 2001. InnoRa contributes over 20 years of experience in cardiovascular device development and clinical trial translation. The partnership includes an undisclosed investment by InnoRa, with Professor Bruno Scheller (co-founder of InnoRa and renowned expert in interventional cardiology) joining CoreMedic's Supervisory Board.
  • Clinical Advisors and KOL NetworkcoreOthersCoreMedic has assembled a network of internationally renowned clinical advisors including Prof. Thierry Carrel (cardiac surgeon with 700+ publications), Prof. Bruno Scheller (interventional cardiology expert), Prof. Maurizio Taramasso, Prof. Alberto Weber (Founder and CMO), and Prof. Rolf Vogel. These key opinion leaders provide scientific and clinical expertise and support the development and adoption of the ChordArt technology.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

CoreMedic GmbH competitors and assessment

Company assessment

Direct peers

  • Abbott: Abbott's MitraClip is the established market leader in transcatheter mitral repair, and the Tendyne system targets transcatheter mitral replacement — directly competing with CoreMedic's ChordArt for the same patient population and cardiology customer base. Abbott's installed-base advantage in catheter-based structural heart interventions makes it the most consequential incumbent.
  • NeoChord: NeoChord develops the NeoChord DS1000 system for beating-heart mitral chordal replacement, the closest technology analog to ChordArt's artificial chord replacement approach. While NeoChord is delivered surgically (transapical) rather than percutaneously, both companies pursue chordal replacement for degenerative MR and target cardiac surgery centers.
  • Edwards Lifesciences: Edwards Lifesciences markets the PASCAL and PASCAL Ace transcatheter mitral valve repair systems, the most direct competitor to CoreMedic's ChordArt in the transcatheter chordal/leaflet repair space. Edwards also sets the bar for transcatheter heart valve trial design and commercialization, and Jodi Akin (CoreMedic's Chair) led seminal global trials and approvals of transcatheter heart valve therapy at Edwards.

Emerging players

  • InnovHeart: InnovHeart is developing the saturn TMVR system for transcatheter mitral valve replacement. It targets the same structural-heart customer base and MR patient population as CoreMedic with a replacement-focused approach.
  • Cardiac Dimensions: Cardiac Dimensions develops the Carillon Mitral Contour System, a transcatheter annuloplasty device for functional mitral regurgitation. It targets an overlapping patient population and customer base (interventional cardiologists and heart teams) with a different but adjacent transcatheter mitral repair mechanism.
  • HighLife Medical: HighLife Medical is developing a transcatheter mitral valve replacement system using a transseptal, transapical valve placement approach. Comparable European medtech with parallel TMVR development and similar regulatory pathway dynamics.
  • Mitralign: Mitralign developed transcatheter annuloplasty systems for functional MR, directly competing for the same heart-failure MR patient segment with a percutaneous approach. Comparable mid-stage transcatheter mitral repair player with similar clinical-trial-stage commercialization pathway.
  • 4C Medical Technologies: 4C Medical is developing the AltaValve system for transcatheter mitral valve replacement (TMVR), addressing mitral regurgitation with a supra-annular implant design. Competitor for the same MR patient population served by CoreMedic, though with a replacement rather than repair approach.

Broad incumbents

  • Medtronic: Medtronic is a broad cardiovascular incumbent with a structural heart portfolio (including Intrepid TMVR) and deep relationships with cardiac surgery centers. Multiple CoreMedic founders held leadership roles at Medtronic and Invatec (acquired by Medtronic), positioning Medtronic as both a talent feeder and potential strategic acquirer.
  • Boston Scientific: Boston Scientific acquired Acotec (co-founded by CoreMedic co-founder Silvio Schaffner) in 2022 for its drug-coated balloon portfolio and is active in structural heart via its Watchman franchise. As a broad incumbent in interventional cardiology, Boston Scientific is both a potential strategic acquirer of CoreMedic and an indirect competitor in structural heart catheter-based therapies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CoreMedic GmbH social profiles

Digital presence

CoreMedic GmbH compliance and trust

Trust signal

Compliance1 record

CoreMedic GmbH financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CoreMedic GmbH leadership team

Management profile

Number of profiles

Profiles12 records

CoreMedic GmbH funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CoreMedic GmbH M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CoreMedic GmbH

What does CoreMedic GmbH do?

CoreMedic develops and manufactures the ChordArt Transcatheter Mitral Valve Repair (TMVr) System, a catheter-based medical device designed to replace damaged or ruptured mitral valve chords through a minimally invasive transfemoral, transseptal percutaneous procedure. The system is sold to cardiac surgery centers and heart valve centers of excellence as a first-line treatment alternative to open-heart surgery for patients with primary mitral regurgitation.

Is CoreMedic GmbH a public or private company?

CoreMedic GmbH is a private company. It is classified as venture growth investor backed and is currently operating.

When was CoreMedic GmbH founded?

CoreMedic GmbH was founded in 2012. It employs 11 to 50 people.

Where is CoreMedic GmbH based?

CoreMedic GmbH is headquartered in Radolfzell, Germany, in the Europe region.

How does CoreMedic GmbH make money?

Two revenue lines are on record. ChordArt TMVr System Sales are the primary driver. The others are professional Services and Training.

Who are CoreMedic GmbH's main competitors?

Direct peers on record are Abbott, NeoChord and Edwards Lifesciences. Emerging players are InnovHeart, Cardiac Dimensions, HighLife Medical, Mitralign and 4C Medical Technologies. Broad incumbents are Medtronic and Boston Scientific.

Does CoreMedic GmbH have an API?

No public API is recorded for CoreMedic GmbH.

What industry is CoreMedic GmbH in?

CoreMedic GmbH's product category is Transcatheter Mitral Valve Repair Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals